Glass House Brands (GLAS) Income from Continuing Operations (2020 - 2026)
Glass House Brands' (GLAS) quarterly Income from Continuing Operations came in at 17006000.0 in Q1 2026, down 9.72% on a QoQ basis from 15500000.0 in Q4 2025.
Glass House Brands (GLAS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Income from Continuing Operations data on file, last reported at 17006000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations changed N/A year-over-year to 17006000.0 in Q1 2026; TTM through Mar 2026 was 35950000.0, a N/A change from a year earlier, with the FY2025 full-year figure at 28952000.0, down 4115.53% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 17006000.0, down from 15500000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for GLAS reached as high as 15168550.0 in Q3 2022 and fell as low as 19659403246000.0 in Q2 2023.
- Historically, Income from Continuing Operations has averaged 2470690482803.85 across 5 years, with a median of 17006000.0 in 2026.
- Across the five-year window, Income from Continuing Operations soared 100.0% in 2022 and plunged 58.76% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 28419588.0 in 2022, then plunged by 49.89% to 42597206.0 in 2023, then soared by 123.57% to 10039000.0 in 2024, then tumbled by 254.4% to 15500000.0 in 2025, then fell by 9.72% to 17006000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 17006000.0 in Q1 2026, 15500000.0 in Q4 2025, and 12188000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | -17.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.01 Mn |
| Dec 31, 2025 | -15.50 Mn |
| Sep 30, 2025 | -12.19 Mn |
| Jun 30, 2025 | 8.74 Mn |
| Jun 30, 2024 | 10.04 Mn |
| Dec 31, 2023 | -42.60 Mn |
| Sep 30, 2023 | 6.28 Mn |
| Jun 30, 2023 | -19,659.40 Bn |
| Mar 31, 2023 | -32.41 Mn |
| Dec 31, 2022 | -28.42 Mn |
| Sep 30, 2022 | 15.17 Mn |
| Jun 30, 2022 | -12,459.44 Bn |
| Mar 31, 2022 | -20.41 Mn |
| Dec 31, 2021 | -18.99 Mn |
| Sep 30, 2021 | -6,955.68 Bn |
| Jun 30, 2021 | -13,606.55 Bn |
| Mar 31, 2021 | -13.15 Mn |
| Dec 31, 2020 | -6.04 Mn |
| Sep 30, 2020 | -1.15 Mn |
| Mar 31, 2020 | -5.14 Mn |